Modelling of the relationship between systolic blood pressure and glucose with the magnesium ion present in the blood plasma: an approach using artificial neural networks

Artificial neural networks became an attractive alternative for modeling and simulation of com- plex biological systems. In the present work, a blood plasma model based on artificial neural networks was proposed in order to evaluate the relationship between the magnesium ion pre-sent in the blood plasma and systolic blood pressure and glucose. Experimental and simu- lated data were used to construct and validate the model. It performed the analysis consider-ing the systolic blood pressure and glucose as a function of magnesium ion concentration at a fixed temperature (37oC). Predictions of these relationships through the proposed model produced errors, on average, below 1% com-pared against experimental data not presented in the training step. The proposed methodology revealed quantitative results and correctly pre-dicted behaviors and trends towards the asso-ciation between magnesium concentrations and systolic blood pressure, and glucose in far agreement with experimental results from lit-erature. These results indicated that artificial neural networks can successfully learn the complexity of the relationships among bio-logical parameters of distinct groups and can be used as a complementary tool to assist studies in which the role of magnesium in systolic blood pressure and glucose are con-sidered.

Determination of Magnesium in whole Blood and Serum of Ischemic Heart Disease(IHD) Patients by Flame Atomic Absorption Spectrometry

Flame atomic absorption spectrometric determination of magnesium in whole blood and serum of ischemic heart disease patients and control with different ages and sex was proposed. The limiting interfering phosphate/magnesium ratio have been estimates.2%w/v AlCl3.6H2O was found to be very influential in removing phosphate interference effects. The detection limit was 0.065 μg/mL .Magnesium added to blood and serum sample, and carried through this method may be recovered completely (96% - 100%) recovery percentage. The suggested method is simple, fast and selective. The statistical analysis of magnesium levels in blood and serum showed that blood and serum magnesium levels in patients were lower than magnesium contents of control group. Magnesium levels in blood and serum of males were significantly lower than females and the magnesium levels were age independent. These findings indicates that there was an association between blood and serum magnesium deficiency which can induce an entire array of path physiological phenomena known to be important in ischemic heart disease.

硫酸镁联合布地奈德治疗哮喘患儿的效果

目的:探讨硫酸镁联合布地奈德治疗哮喘患儿的效果。方法:选取2020年2月—2023年2月南宁市第二人民医院儿科收治的90例哮喘患儿。根据随机数字排序将其分为治疗组与基础组,各45例。基础组给予布地奈德治疗,治疗组在基础组基础上给予硫酸镁注射液。比较两组临床疗效,治疗前后肺功能、血气指标、哮喘情况、炎症因子及镁离子水平。结果:治疗组总有效率高于基础组,差异有统计学意义(P<0.05)。治疗后,两组用力肺活量(FVC)、呼气峰流速(PEF)、第1秒用力呼气容积(FEV_(1))占预计值的百分比(FEV_(1)%pred)、FEV_(1)均升高,治疗组FVC、PEF、FEV_(1)%pred、FEV_(1)均高于基础组,差异有统计学意义(P<0.05)。治疗后,两组血氧分压(PaO_(2))、酸碱度(pH)、血氧饱和度(SaO_(2))均升高,二氧化碳分压(PaCO_(2))降低,治疗组PaO_(2)、pH、SaO_(2)均高于基础组,PaCO_(2)低于基础组,差异有统计学意义(P<0.05)。治疗后,两组儿童哮喘控制测试评分表(C-ACT)评分、镁离子水平均升高,白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、白细胞介素-5(IL-5)水平均降低,治疗组C-ACT评分、镁离子水平均高于基础组,IL-1、TNF-α、IL-5水平均低于基础组,差异有统计学意义(P<0.05)。结论:硫酸镁联合布地奈德对哮喘患儿的治疗效果较好,且明显优于单一激素治疗,能够显著改善患儿的临床症状,对炎症因子、血气指标、肺功能等哮喘相关指标的改善作用明显。

硝苯地平、硫酸镁联合地西泮在重度子痫前期患者临床治疗中的应用价值

目的:探讨硝苯地平、硫酸镁联合地西泮在重度子痫前期(PE)患者中的应用效果。方法:选取2021年5月—2023年5月仁怀市人民医院收治的100例重度PE患者作为研究对象,按随机数表法将其分为观察组与对照组,各50例。对照组给予硝苯地平、硫酸镁治疗,观察组在对照组基础上加用地西泮治疗。对比两组临床疗效、血压水平、24 h尿蛋白、血清学指标及不良反应发生情况。结果:观察组总有效率为96.00%,高于对照组的82.00%,差异有统计学意义(P<0.05)。两组治疗前血压、24 h尿蛋白、血清学指标比较,差异无统计学意义(P>0.05);观察组治疗后收缩压(SBP)、舒张压(DBP)、24 h尿蛋白、氧化蛋白产物(AOPP)、血管紧张素Ⅱ(Ang-Ⅱ)低于对照组,谷胱甘肽过氧化物酶(GSH-Px)、血管内皮生长因子(VEGF)高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:硝苯地平、硫酸镁联合地西泮可增强重度PE治疗效果,降低血压与24 h尿蛋白水平,改善血清学指标,安全性良好。

硝苯地平联合硫酸镁治疗妊娠高血压综合征的临床安全性研究

目的分析妊娠高血压综合征(Hypertensive Disorder Complicating Pregnancy,HDCP)实施硝苯地平+硫酸镁治疗的安全性。方法选取2020年11月—2023年11月日照市中心医院收治的83例HDCP患者作为研究对象,按随机数表法分为普通组(n=41)、调查组(n=42)。普通组行硫酸镁治疗,调查组联合硝苯地平治疗,比较两组血压指标、子宫血流情况、肾功能,评估安全性。结果治疗后,两组舒张压和收缩压水平均下降,其中调查组(71.36±4.98)、(118.02±7.07)mmHg低于普通组,差异有统计学意义(t=8.028、6.988,P均<0.05);治疗后两组搏动指数、阻力指数以及收缩峰值流速均下降,其中调查组低于普通组,差异有统计学意义(P均<0.05);治疗后两组肌酐以及24 h尿蛋白均下降,其中调查组低于普通组,差异有统计学意义(P均<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论硝苯地平+硫酸镁具有一定的安全性,能降低血压,改善各HDCP患者子宫位置的血流情况,还能预防肾脏损伤。

硫酸镁联合拉贝洛尔治疗妊娠高血压的效果及对收缩压、舒张压水平的影响

目的 分析将硫酸镁联合拉贝洛尔治疗方案应用于妊娠高血压患者,对其收缩压、舒张压水平产生的影响。方法 回顾性选取2019年3月—2022年5月福建省泉州市中医院的100例妊娠高血压患者的临床资料,以治疗方法的不同分为两组,每组50例,接受硫酸镁常规治疗的为对照组,硫酸镁联合拉贝洛尔治疗的为观察组,比较两组临床疗效、血管内皮功能、血压水平、炎性应激反应、不良反应发生率以及不良结局发生率。结果 观察组临床疗效(98.00%)高于对照组(86.00%),差异有统计学意义(χ^(2)=4.891,P<0.05)。治疗后,观察组各项血管内皮功能指标均优于对照组,观察组血压水平均低于对照组,观察组各项炎性应激反应指标均优于对照组,观察组不良反应发生率及不良结局发生率均低于对照组,差异有统计学意义(P均<0.05)。结论 与常规治疗方案相比,硫酸镁基础上联合拉贝洛尔治疗妊娠高血压的效果更为显著。

甲磺酸酚妥拉明联合硝苯地平及硫酸镁治疗妊娠高血压综合征的临床效果观察

目的 观察甲磺酸酚妥拉明联合硝苯地平及硫酸镁治疗妊娠高血压综合征的临床效果。方法选取2021年4月至2022年4月我院收治的98例妊娠高血压综合征患者,随机分为两组各49例。对照组采用硫酸镁治疗,观察组在对照组基础上采用甲磺酸酚妥拉明联合硝苯地平治疗,均连续治疗7 d。比较两组的治疗效果、血压及不良妊娠结局。结果 观察组治疗总有效率为95.92%,高于对照组的79.59%(P <0.05)。治疗7 d后,两组收缩压、舒张压均低于治疗前,且观察组收缩压、舒张压均低于对照组(P <0.05)。观察组不良妊娠结局发生率为8.16%,低于对照组的26.53%(P <0.05)。结论 甲磺酸酚妥拉明联合硝苯地平及硫酸镁治疗妊娠高血压综合征,可明显提升临床疗效,降低患者血压和不良妊娠结局发生风险。

拉贝洛尔联合硫酸镁治疗妊娠期高血压疾病的效果观察

目的 探究拉贝洛尔联合硫酸镁在妊娠期高血压疾病中的治疗效果。方法 将河南科技大学附属许昌市中心医院2022年6月至2023年10月收治的86例妊娠期高血压患者根据随机数字表法分为对照组(43例,硫酸镁治疗)与试验组(43例,拉贝洛尔联合硫酸镁治疗),对比两组治疗情况。结果 治疗后,两组血压水平与24 h尿蛋白定量均下降,且试验组较对照组低,差异均有统计学意义(P <0.05)。试验组治疗有效率(97.67%)高于对照组(83.72%),差异具有统计学意义(P <0.05)。试验组产妇不良结局发生率(2.32%)、新生儿不良结局发生率(0)低于对照组(13.95%、9.30%),差异均有统计学意义(P <0.05)。两组患者不良反应发生率对比,差异无统计学意义(P> 0.05)。结论 在妊娠期高血压疾病患者中联合拉贝洛尔与硫酸镁治疗,可改善其血压水平与24 h尿蛋白定量,提升治疗有效率,降低不良结局发生率,安全可靠。

米索前列醇联合硫酸镁对妊娠高血压综合征产后出血量及血压的影响观察

目的研究妊娠高血压综合征产妇采取米索前列醇联合硫酸镁治疗对血压及产后出血量的影响。方法选取66例妊娠高血压综合征产妇,经区组随机化分组法分为对照组和观察组,每组33例。对照组产妇采取硫酸镁治疗,观察组产妇采取米索前列醇联合硫酸镁治疗。比较两组产妇产后出血量、血压、凝血功能、应激反应以及不良妊娠结局发生率。结果观察组产后2、24 h出血量分别为(198.31±15.20)、(296.09±16.12)ml,均少于对照组的(289.09±17.73)、(403.07±18.02)ml(P<0.05)。与治疗前比较,两组治疗后舒张压、收缩压、平均动脉压均下降,差异有统计学意义(P<0.05);但治疗后两组舒张压、收缩压、平均动脉压比较,差异无统计学意义(P>0.05)。与治疗前比较,两组治疗后纤维蛋白原均下降,凝血酶原时间、活化部分凝血活酶时间均延长,且观察组治疗后纤维蛋白原(3.96±0.72)g/L高于对照组的(3.26±0.88)g/L,凝血酶原时间(10.93±1.26)s、活化部分凝血活酶时间(31.28±2.09)s均短于对照组的(12.35±1.81)、(35.18±2.87)s(P<0.05)。与治疗前比较,两组治疗后丙二醛(MDA)均下降,超氧化物歧化酶(SOD)均上升,且观察组治疗后MDA(12.90±1.59)nmol/ml低于对照组的(17.86±2.15)nmol/ml,SOD(123.78±12.96)U/ml高于对照组的(90.45±9.68)U/ml(P<0.05)。观察组不良妊娠结局发生率9.09%比对照组的30.30%更低(P<0.05)。结论米索前列醇与硫酸镁联治能够有效改善妊娠高血压综合征产妇的血压水平,减少产后出血量及不良妊娠结局发生率,具有推广应用意义。

硝苯地平联合硫酸镁治疗妊娠期高血压患者的疗效分析

目的分析硝苯地平联合硫酸镁治疗妊娠期高血压(PIH)患者的疗效。方法选取贵州省黔西南州人民医院产科2022年1月至2023年12月收治的100例PIH患者,根据不同疗法纳入对照组(50例)与观察组(50例),对照组予以硝苯地平治疗,观察组予以硝苯地平联合硫酸镁治疗,对比两组的血压水平(SBP、DBP)、尿肌酐与尿蛋白水平、心率(产妇、胎儿)、临床疗效、不良反应(恶心呕吐、头晕、皮肤瘙痒、消化道出血)、不良妊娠结局(宫颈裂伤、过度宫缩、急产、产后出血、新生儿窒息)。结果两组治疗后的SBP、DBP均降低,且观察组低于对照组,P<0.05;两组治疗后的尿肌酐与尿蛋白均降低,且观察组低于对照组,P<0.05;两组治疗后产妇、胎儿的心率均降低,且观察组低于对照组,P<0.05;观察组总有效率高于对照组,P<0.05;两组不良反应发生率相近,P>0.05;观察组不良妊娠结局发生率低于对照组,P<0.05。结论硝苯地平联合硫酸镁治疗PIH患者的疗效较好,可有效控制患者血压,改善尿肌酐与尿蛋白水平,降低母婴心率,改善妊娠结局,且不良反应少。

Magnesium:pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Intracerebral hemorrhage(ICH) remains the second-most common form of stroke with high morbidity and mortality.ICH can be divided into two pathophysiological stages:an acute primary phase,including hematoma volume expansion,and a subacute secondary phase consisting of blood-brain barrier disruption and perihematomal edema expansion.To date,all major trials for ICH have targeted the primary phase with therapies designed to reduce hematoma expansion through blood pressure control,surgical evacuation,and hemostasis.However,none of these trials has resulted in improved clinical outcomes.Magnesium is a ubiquitous element that also plays roles in vasodilation,hemostasis,and blood-brain barrier preservation.Animal models have highlighted potential therapeutic roles for magnesium in neurological diseases specifically targeting these pathophysiological mechanisms.Retrospective studies have also demonstrated inverse associations between admission magnesium levels and hematoma volume,hematoma expansion,and clinical outcome in patients with ICH.These associations,coupled with the multifactorial role of magnesium that targets both primary and secondary phases of ICH,suggest that magnesium may be a viable target of study in future ICH studies.

Comparative induction of controlled circulation by magnesium and remifentanil in spine surgery

AIM: To evaluate the efficacy of magnesium sulfate(MGS) in comparison with remifentanil for induction of relative hypotension in posterior fusion of spine(PSF).METHODS: In this randomized clinical trial, 40 patients with the American Society of Anesthesiologists Ⅰ and Ⅱ physical status undergoing lumbar PSF were randomized to receive remifentanil(REM) 0.15 μg/kg or MGS 50 mg/kg for controlled hypotension. The administering anesthesiologist was blinded to the medication. Continuous infusion was maintained at a fixed volume rate to deliver precalculated doses of either study drugs. All other aspects of anesthesia and surgery were similar in the two groups. The target mean arterial pressure(MAP) range used in this study was 60-70 mm Hg. In the course of surgery, the hemodynamic variables, volumeof blood loss, urine output, fluid intake and surgeon's satisfaction were recorded. Data was analyzed with SPSS version 13.0 and P values less than 0.05 were considered significant.RESULTS: Twenty patients in the MGS group and 19 patients in the REM group were studied. There was no difference between the two groups in the hemodynamic variables, blood loss, urine output, fluid requirement and surgeon's satisfaction for exposure. The target MAP was achieved in 75% of Mg and 58% of remifentanil groups. Although a higher number of patients in the REM group required nitroglycerin(42.1%) to reach the target MAP than those in the MGS group(25%), this difference was not statistically significant(P = 0.32).CONCLUSION: Our findings showed that in patients undergoing lumbar PSF surgery, remifentanil and MGS have a similar hypotensive effect and comparable amount of blood loss without any significant adverse effects.

铝镁匹林片(Ⅱ)联合阿托伐他汀钙在脑梗死治疗中的作用分析

探讨铝镁匹林片(Ⅱ)联合阿托伐他汀钙在脑梗死治疗中的作用及其安全性。选取遵义市妇幼保健院2020年5月—2023年5月收治的40例脑梗死患者为研究对象,随机将其分为对照组和研究组,每组患者各20例。对照组服用阿托伐他汀钙片,研究组在此基础上服用铝镁匹林片(Ⅱ),从患者临床疗效、炎性因子指标和血脂指标的变化情况对比两组不同效果。结果显示,研究组临床治疗总有效率更高(P<0.05);治疗前两组炎性因子和血脂水平均无显著差异(P>0.05),治疗后患者上述指标均有不同程度改善,研究组各项指标改善程度更显著(P<0.05)。研究发现,通过铝镁匹林片(Ⅱ)联合阿托伐他汀钙治疗脑梗死,可以改善患者的炎性因子指标,降低其血脂水平,证实联合治疗方法具有良好的临床效果,并且对患者的预后有着积极的影响,值得应用推广。

合并骨质疏松且无低血镁的Gitelman综合征1例

目的探讨Gitelman综合征(GS)合并重度骨质疏松的临床特点、诊断和治疗,加深对该病的认识。方法2017年2月海南医学院第二附属医院内分泌科住院的GS合并重度骨质疏松且无低血镁1例,复习文献,总结该病特点。结果该病主要表现为严重低钾血症、多处骨关节疼痛,易误诊。予积极补钾、抗醛固酮、抗骨质疏松治疗,有效缓解了病情。结论GS虽然尿钙低,无低血镁,但也可以合并骨质疏松。因此,对存在多关节疼痛的GS病人,应及时进行双能X线骨密度检查早期筛查骨质疏松。对于此类病人,积极给予补钾、抗醛固酮及抗骨质疏松治疗可提高疗效。

Spectrofluorimetric Determination of Magnesium (Ⅱ) with 7-(8-Hydroxy-3, 6-Disulfonaphthylazo)-8-Hydroxyquinoline-5-Sulfonic Acid

A new fluorescent reagent, 7 (8 hydroxy 3, 6 disulfonaphthylazo) 8 hydroxyquinoline 5 sulfonic acid (HDNHQ) for the determination of magnesium has been developed. It reacted with magnesium to form a 1∶1 fluorescent complex with λ ex / λ em =356/495 nm immediately at room temperature in ammonia ammonium chloride buffer (pH 10.7). A linear relationship was obtained in the magnesium concentration range of 0 160 ng·mL -1 with the detection limit of 0.04 ng·mL -1 . The proposed method was simple, rapid and sensitive. It has been successfully applied to the determination of trace magnesium in blood serum with recoveries of 103.75% and 98.16%, respectively.

Low Dietary Magnesium Intake and Hypertension

Purpose: Magnesium (Mg) is a key factor in blood pressure regulation. However, only in recent years, magnesium dietary intake has been studied in relation to hypertension, with equivocal conclusions. Further no comparisons have previously been made between the UK general population and primary hypertensives, the UK RNI and the USARDA. Methods: Twenty-five hypertensives (HT) (mean age 63.4 y) and twenty-one normotensives (mean age 46.7 y) were recruited from the same geographical area. Food diaries were completed and analysed to determine average daily Mg intake. Mg intake was compared between the observed group (OB), normotensives (NT) and general population (GP) and both the UK RNI and the USA RDA. Results: Study participants had a significantly lower dietary Mg intake than the UK RNI (p Conclusions: Daily Mg intake in hypertensives is lower than the general population, the UK RNI and the USA RDA. Daily magnesium intake reduces with age. These findings suggest that low Mg dietary intake increases the risk of hypertension.

The Effects of Magnesium-EDTA Chelation Therapy on Arterial Stiffness

Traditional risk factors for cardiovascular disease can only assess risks for groups of people. New parameters of arterial stiffness are more reliable for predicting cardiovascular outcomes for individuals with and without a cardiovascular history. The objective of this study was to assess the effects of Magnesium-EDTA chelation therapy using new methods and parameters such as pulse wave velocity (PWV), central blood pressure (SBPao) and endothelial function (Aix). We followed 43 patients with an abnormal PWV and SBPao, setting them up in two groups. The 21 patients in Group A had already been diagnosed with cardiovascular disease. The other 22 patients in Group B also showed abnormal PWV, SBPao and Aix, but showed no cardiovascular symptoms. Each patient in Groups A and B received one Mg-EDTA treatment per week. The total treatment plan consisted of 25 Mg-EDTA chelation treatments according to the standard protocol of IBCMT. After 25 Mg-EDTA chelation sessions, PWV and SBPao improved significantly in all patients of Groups A and B. In addition, Aix improved significantly in these patients, but remained abnormal. Group C included 18 asymptomatic patients with normal PWV or SBPao. Aix was abnormal in this group, but to a much lesser extent than Groups A and B. The 18 asymptomatic patients of Group C did not receive Mg-EDTA treatment. Observation showed no significant changes in all three parameters of arterial stiffness. The results of this study indicate that a course of treatment with Magnesium-EDTA chelation therapy significantly lowers cardiovascular risks. We conclude that Mg-EDTA chelation therapy improves PWV as an indicator of arterial stiffness, SBPao (central blood pressure) as an indicator of aortic elasticity and Aix (augmented aortic index) as an indicator of endothelial functioning. These improvements in PWV, SBPao and Aix demonstrate that atherosclerosis is a dynamic and (partially) reversible process.

妊娠期高血压疾病的产科临床治疗效果分析

目的探讨并分析妊娠期高血压疾病的产科临床治疗效果。方法选取我院2021年9月至2023年8月期间收治的188例妊娠期高血压疾病患者展开研究,遵循随机数字表法分组原则,将其分为参照组(硫酸镁治疗)与试验组(硫酸镁联合硝苯地平治疗),每组94例。观察两组血压水平、血清学指标、治疗疗效、不良反应以及妊娠结局。结果治疗前,两组患者收缩压、舒张压水平并无显著差异,P>0.05;治疗后,两组患者收缩压、舒张压水平均有所降低,而且试验组患者收缩压、舒张压水平均低于参照组,P<0.05。试验组CRP、Hcy、MDA、TAC、SOD、GSH-Px、治疗有效率、不良反应发生率均优于参照组,P<0.05。两组在新生儿病死率上差异无统计学意义,P>0.05;但试验组剖宫产率21.28%、产后出血率4.26%、早产率2.13%、新生儿窒息率1.06%,均低于参照组的43.62%、12.77%、15.96%、11.70%,P<0.05。结论硫酸镁联合硝苯地平治疗妊娠期高血压疾病的临床效果显著,可有效地控制患者血压水平,改善血清学指标,提高临床治疗有效性,并降低不良反应,改善妊娠结局。

盐酸拉贝洛尔联合硫酸镁对妊娠期高血压患者的临床作用分析

目的探讨盐酸拉贝洛尔、硫酸镁联合治疗方案用于妊娠期高血压中的效果。方法方便选取2016年1月—2019年12月盐城市妇幼保健院收治的120例妊娠期高血压患者为研究对象,采用随机数表法分为参照组和治疗组,各60例。两组均接受降压、利尿、解痉、改善微循环等基础治疗,参照组采用硫酸镁治疗,治疗组在对照组基础上联合盐酸拉贝洛尔治疗。比较两组患者血压水平、血液相关指标和母婴结局。结果治疗前,两组患者血压指标、血液相关指标相似,差异无统计学意义(P>0.05);治疗1个月后,两组患者血压指标、血液相关指标均发生明显变化,治疗组舒张压(87.43±4.02)mmHg以及收缩压(134.20±8.88)mmHg均低于参照组的(90.54±4.34)mmHg、(148.06±10.32)mmHg,差异有统计学意义(t=4.072、7.886,P<0.05)。治疗组血清血管内皮生长因子(40.02±2.88)ng/L、血清基质金属蛋白酶-9(92.18±7.38)ng/mL高于对照组(34.76±3.60)ng/L、(80.54±7.98)ng/mL,血小板α颗粒膜蛋白140水平(11.03±1.89)μg/L低于参照组(13.88±2.01)μg/L,差异有统计学意义(t=8.838、8.295、8.001,P<0.05)。治疗组不良母婴结局与5 min Apgar<8分总发生率(6.67%)低于参照组(20.00%),差异有统计学意义(χ^(2)=4.615,P<0.05)。结论妊娠期高血压患者接受盐酸拉贝洛尔、硫酸镁联合治疗方案可更好地控制血压、改善血液指标以及母婴结局。

老年维持性血液透析病人血镁水平及其临床意义

目的调查老年维持性血液透析(maintenance hemodialysis,MHD)病人血镁水平,分析不同血镁水平病人的血压、全段甲状旁腺激素(intact parathyroid hormone,iPTH)水平及营养状况。方法选择99例透析充分的老年MHD病人,根据透析前血镁水平将病人分为低镁组(<0.75 mmol/L,n=24)、正常组(0.75~1.02 mmol/L,n=45)和高镁组(>1.02 mmol/L,n=30),比较3组透析前血钙、血磷、iPTH、血浆白蛋白、Hb的水平以及透析中和透析间期的血压。结果不同血镁水平病人透析间期血压无明显变化,低镁组透析中SBP明显低于正常组和高镁组(P<0.01),DBP明显低于正常组(P<0.01)。3组间血iPTH、血钙、血磷、Hb水平按低镁组、高镁组、正常组依次升高,且3组间差异均有统计学意义(均P<0.01);正常组血浆白蛋白和Hb水平明显高于低镁组(P<0.05)。结论老年MHD病人血镁水平正常或升高者通常营养指标较好,透析中血压相对稳定,同时iPTH水平偏高。